Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study

Carfilzomib has improved survival in patients with relapsed/refractory multiple myeloma (RRMM), but it may exert cardiovascular adverse events (CVAEs). The aim of this study was to assess whether treatment with daratumumab may ameliorate carfilzomib-related toxicity. We prospectively evaluated 25 pa...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Kimon Stamatelopoulos, Nikolaos Makris, Georgios Georgiopoulos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Ageliki Laina, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Nikolaos Kanellias, Panagiotis Malandrakis, Dimitris Delialis, Ioanna Andreadou, Efstathios Kastritis, Meletios A. Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
carfilzomib
multiple myeloma
daratumumab
cardiovascular
heart
toxicity
Online Access:https://www.mdpi.com/2072-6694/13/20/5057

Internet

https://www.mdpi.com/2072-6694/13/20/5057

Similar Items